The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

Authors:

Abstract
No abstract available
Funding Information
  • Eli Lilly and Company
  • Merck Sharp and Dohme United Kingdom
  • Pfizer
  • Les Laboratories Pierre Fabre
  • AstraZeneca
  • Gilead UK and Ireland Corporate Contributions
  • Bayer
  • Vifor Pharma
  • Teva Pharmaceutical Industries
  • Novartis
  • PharmaMar
  • Roche
  • Ipsen
  • Sanofi
  • Gilead Sciences
  • Bristol-Myers Squibb
  • European Society for Medical Oncology
  • Merck
  • Servier
  • GlaxoSmithKline

This publication has 25 references indexed in Scilit: